Post removed.Why?

Post removed.Why?

Post removed.Why?

Those who take mRNA vaccines most probably their off spring will be like erlangsheng semukong n chupachiek reborn

Post removed.Why?

Post removed.Why?

Post removed.Why?

NETX major shareholder is King of manipulator aka goreng kaki FINTECH the conman

Stockraider, you very funny. NETX loss stock, keep asking to buy. Top glove make so much profit, keep asking to sell. Since Top Glove no good, you don't have to waste time here. Funny people.
13/12/2020 4:21 PM

NETX major shareholder is King of manipulator aka goreng kaki FINTECH the conman

Stockraider, you very funny. NETX loss stock, keep asking to buy. Top glove make so much profit, keep asking to sell. Since Top Glove no good, you don't have to waste time here. Funny people.

Those who take mRNA vaccines most probably their off spring will be like erlangsheng semukong n chupachiek reborn

Those who take mRNA vaccines most probably their off spring will be like erlangsheng semukong n chupachiek reborn

Post removed.Why?

Bintai the con n goreng stock
52 week High n Low

From low of 0.04 to high of 1.47 n close 1.12 already 3000%

More than any gloves stock high

So guys dont kena cheated by these 2 con artist Victorino n joyvest
13/12/2020 3:19 PM

Convid 19 keep mutating , 9 months old vaccine wont be so effective
SOP of any emergency safe n effective vaccine should be at least 18-24 months

Convid 19 keep mutating , 9 months old vaccine wont be so effective
SOP of any emergency safe n effective vaccine should be at least 18-24 months

Convid 19 keep mutating , 9 months old vaccine wont be so effective
SOP of any emergency safe n effective vaccine should be at least 18-24 months

Convid 19 keep mutating , 9 months old vaccine wont be so effective
SOP of any emergency safe n effective vaccine should be at least 18-24 months

TP 3.50 ? Everybody rushing to take private TG

Vaccine makers, including two of the biggest in the world, suffered setbacks in the push to get more Covid-19 shots across the line, tempering a run of positive news.
Sanofi and GlaxoSmithKline Plc delayed advanced trials of their experimental Covid-19 shot after it failed to produce a strong enough response in older people, pushing its potential availability to the end of next year. In another blow, trials of a vaccine being developed by CSL Ltd. and the University of Queensland in Australia ran into difficulties.
Sanofi and its U.K. partner will begin a new second-phase study with a more concentrated antigen in February after they said the current dosage failed to generate a good immune response in people 50 years and older. Younger adults showed a response similar to patients who have recovered from the disease.
The problem arose after two different reagents used to measure vaccine formulations provided inaccurate information about the concentration of antigens, Sanofi said in an emailed statement. The companies notified U.S. officials about the matter.
The delay underscores the difficulties and uncertainties companies face in developing shots in record time against a disease that’s already claimed more than 1.5 million lives. It’s also a blow for governments that were counting on supplies from the two vaccine giants amid expectations the world will need multiple inoculations to stop the spread of the pathogen.
Australia meanwhile canceled an order for 51 million doses of a Covid shot being developed by CSL and the Australian university. A component of the vaccine comes from the human immunodeficiency virus, and while that posed no risk of infection, some trial participants had false positive tests for HIV.

The announcements temper some of the optimism following positive trial results from Pfizer Inc. and Moderna Inc. Another inoculation from AstraZeneca Plc and the University of Oxford looks promising, too, despite questions about its effectiveness in older adults. The U.K. and Canada have already approved a shot from Pfizer and partner BioNTech SE that employs messenger RNA technology, and the U.S. and Europe may do so soon. China and Russia have already begun administering their own vaccinations.
Sanofi fell as much as 3.3% Friday in Paris, while Glaxo was little changed in London.


https://www.bloomberg.com/news/articles/2020-12-11/sanofi-gsk-delay-covid-vaccine-after-elderly-get-little-boost

Vaccine makers, including two of the biggest in the world, suffered setbacks in the push to get more Covid-19 shots across the line, tempering a run of positive news.
Sanofi and GlaxoSmithKline Plc delayed advanced trials of their experimental Covid-19 shot after it failed to produce a strong enough response in older people, pushing its potential availability to the end of next year. In another blow, trials of a vaccine being developed by CSL Ltd. and the University of Queensland in Australia ran into difficulties.
Sanofi and its U.K. partner will begin a new second-phase study with a more concentrated antigen in February after they said the current dosage failed to generate a good immune response in people 50 years and older. Younger adults showed a response similar to patients who have recovered from the disease.
The problem arose after two different reagents used to measure vaccine formulations provided inaccurate information about the concentration of antigens, Sanofi said in an emailed statement. The companies notified U.S. officials about the matter.
The delay underscores the difficulties and uncertainties companies face in developing shots in record time against a disease that’s already claimed more than 1.5 million lives. It’s also a blow for governments that were counting on supplies from the two vaccine giants amid expectations the world will need multiple inoculations to stop the spread of the pathogen.
Australia meanwhile canceled an order for 51 million doses of a Covid shot being developed by CSL and the Australian university. A component of the vaccine comes from the human immunodeficiency virus, and while that posed no risk of infection, some trial participants had false positive tests for HIV.

The announcements temper some of the optimism following positive trial results from Pfizer Inc. and Moderna Inc. Another inoculation from AstraZeneca Plc and the University of Oxford looks promising, too, despite questions about its effectiveness in older adults. The U.K. and Canada have already approved a shot from Pfizer and partner BioNTech SE that employs messenger RNA technology, and the U.S. and Europe may do so soon. China and Russia have already begun administering their own vaccinations.
Sanofi fell as much as 3.3% Friday in Paris, while Glaxo was little changed in London.


https://www.bloomberg.com/news/articles/2020-12-11/sanofi-gsk-delay-covid-vaccine-after-elderly-get-little-boost

Vaccine makers, including two of the biggest in the world, suffered setbacks in the push to get more Covid-19 shots across the line, tempering a run of positive news.
Sanofi and GlaxoSmithKline Plc delayed advanced trials of their experimental Covid-19 shot after it failed to produce a strong enough response in older people, pushing its potential availability to the end of next year. In another blow, trials of a vaccine being developed by CSL Ltd. and the University of Queensland in Australia ran into difficulties.
Sanofi and its U.K. partner will begin a new second-phase study with a more concentrated antigen in February after they said the current dosage failed to generate a good immune response in people 50 years and older. Younger adults showed a response similar to patients who have recovered from the disease.
The problem arose after two different reagents used to measure vaccine formulations provided inaccurate information about the concentration of antigens, Sanofi said in an emailed statement. The companies notified U.S. officials about the matter.
The delay underscores the difficulties and uncertainties companies face in developing shots in record time against a disease that’s already claimed more than 1.5 million lives. It’s also a blow for governments that were counting on supplies from the two vaccine giants amid expectations the world will need multiple inoculations to stop the spread of the pathogen.
Australia meanwhile canceled an order for 51 million doses of a Covid shot being developed by CSL and the Australian university. A component of the vaccine comes from the human immunodeficiency virus, and while that posed no risk of infection, some trial participants had false positive tests for HIV.

The announcements temper some of the optimism following positive trial results from Pfizer Inc. and Moderna Inc. Another inoculation from AstraZeneca Plc and the University of Oxford looks promising, too, despite questions about its effectiveness in older adults. The U.K. and Canada have already approved a shot from Pfizer and partner BioNTech SE that employs messenger RNA technology, and the U.S. and Europe may do so soon. China and Russia have already begun administering their own vaccinations.
Sanofi fell as much as 3.3% Friday in Paris, while Glaxo was little changed in London.


https://www.bloomberg.com/news/articles/2020-12-11/sanofi-gsk-delay-covid-vaccine-after-elderly-get-little-boost

Vaccine makers, including two of the biggest in the world, suffered setbacks in the push to get more Covid-19 shots across the line, tempering a run of positive news.
Sanofi and GlaxoSmithKline Plc delayed advanced trials of their experimental Covid-19 shot after it failed to produce a strong enough response in older people, pushing its potential availability to the end of next year. In another blow, trials of a vaccine being developed by CSL Ltd. and the University of Queensland in Australia ran into difficulties.
Sanofi and its U.K. partner will begin a new second-phase study with a more concentrated antigen in February after they said the current dosage failed to generate a good immune response in people 50 years and older. Younger adults showed a response similar to patients who have recovered from the disease.
The problem arose after two different reagents used to measure vaccine formulations provided inaccurate information about the concentration of antigens, Sanofi said in an emailed statement. The companies notified U.S. officials about the matter.
The delay underscores the difficulties and uncertainties companies face in developing shots in record time against a disease that’s already claimed more than 1.5 million lives. It’s also a blow for governments that were counting on supplies from the two vaccine giants amid expectations the world will need multiple inoculations to stop the spread of the pathogen.
Australia meanwhile canceled an order for 51 million doses of a Covid shot being developed by CSL and the Australian university. A component of the vaccine comes from the human immunodeficiency virus, and while that posed no risk of infection, some trial participants had false positive tests for HIV.

The announcements temper some of the optimism following positive trial results from Pfizer Inc. and Moderna Inc. Another inoculation from AstraZeneca Plc and the University of Oxford looks promising, too, despite questions about its effectiveness in older adults. The U.K. and Canada have already approved a shot from Pfizer and partner BioNTech SE that employs messenger RNA technology, and the U.S. and Europe may do so soon. China and Russia have already begun administering their own vaccinations.
Sanofi fell as much as 3.3% Friday in Paris, while Glaxo was little changed in London.


https://www.bloomberg.com/news/articles/2020-12-11/sanofi-gsk-delay-covid-vaccine-after-elderly-get-little-boost

Next week Solution the con n goreng stock will be like VIVOCOM limit down 2 x recently

tut tut

Solution the con n goreng stock
52 week High n Low

From low of 0.05 to high of 2.00 n close 1.68 already more than 3000 %

More than any gloves stock high

So guys dont kena cheated by these con artist joyvest

Price History of con n goreng stock Solution

Promote by best snake oil salesman ie joyvest




Date Open High Low Close Volume Value Transactions
Week : 33
13/08/2020 0.260 0.265 0.240 0.250 9.053m 2.292m 381
12/08/2020 0.230 0.255 0.225 0.250 17.552m 4.244m 785
11/08/2020 0.285 0.290 0.205 0.220 16.615m 4.178m 709
10/08/2020 0.300 0.300 0.265 0.275 18.939m 5.315m 755
Week : 32
07/08/2020 0.230 0.300 0.230 0.250 39.877m 10.396m 1,738
06/08/2020 0.165 0.200 0.160 0.200 18.569m 3.319m 687
05/08/2020 0.145 0.165 0.145 0.160 20.694m 3.113m 723
04/08/2020 0.110 0.135 0.105 0.135 20.225m 2.447m 507
03/08/2020 0.100 0.110 0.095 0.105 3.978m 407,750.50 119
Week : 31
30/07/2020 0.095 0.100 0.095 0.100 2.094m 200,326.00 50
29/07/2020 0.100 0.105 0.095 0.100 484,700 48,250.00 21
28/07/2020 0.100 0.105 0.095 0.100 1.125m 112,207.50 52
27/07/2020 0.100 0.105 0.100 0.105 686,700 69,093.50 27
Week : 30
24/07/2020 0.105 0.110 0.095 0.100 2.353m 238,466.50 71
23/07/2020 0.100 0.110 0.100 0.110 3.499m 363,561.50 102
22/07/2020 0.100 0.100 0.095 0.100 1.330m 132,800.00 46
21/07/2020 0.090 0.100 0.090 0.095 3.282m 316,198.50 156
20/07/2020 0.090 0.095 0.090 0.090 587,500 52,982.50 21
Week : 29
17/07/2020 0.090 0.095 0.090 0.095 590,200 53,368.00 22
16/07/2020 0.090 0.090 0.090 0.090 1.286m 115,704.00 37
15/07/2020 0.090 0.100 0.085 0.095 3.159m 292,292.00 60
14/07/2020 0.090 0.090 0.085 0.085 2.030m 180,457.00 48
13/07/2020 0.095 0.095 0.090 0.090 1.872m 170,280.00




Date Open High Low Close Volume Value Transactions
Week : 16
13/04/2020 0.060 0.060 0.060 0.060 242,100 14,526.00 10
Week : 15
10/04/2020 0.060 0.060 0.060 0.060 200,000 12,000.00 4
09/04/2020 - 0.000 0.000 0.000 0 0.00 0
08/04/2020 0.060 0.060 0.060 0.060 247,100 14,826.00 18
07/04/2020 0.060 0.065 0.060 0.065 336,000 20,160.50 17
06/04/2020 0.050 0.060 0.050 0.055 751,000 39,535.50 19
Week : 14
03/04/2020 0.055 0.055 0.055 0.055 60,000 3,300.00 2
02/04/2020 0.055 0.055 0.055 0.055 50,000 2,750.00 2
01/04/2020 0.050 0.060 0.050 0.055 434,600 23,165.50 21
31/03/2020 0.055 0.060 0.050 0.055 740,100 38,562.50 21
30/03/2020 0.055 0.055 0.055 0.055 35,000 1,925.00 2
Week : 13
27/03/2020 0.055 0.065 0.055 0.065 823,800 48,610.00 20
26/03/2020 0.050 0.055 0.050 0.055 190,000 10,400.00 6
25/03/2020 0.055 0.060 0.055 0.055 470,100 26,530.50 20
24/03/2020 0.050 0.055 0.050 0.055 96,000 4,825.00 6
23/03/2020 0.050 0.050 0.045 0.050 462,000 21,300.00 13
Week : 12
20/03/2020 0.050 0.055 0.050 0.055 625,000 32,470.00 25
19/03/2020 0.050 0.050 0.045 0.045 917,000 45,550.00 17
18/03/2020 0.050 0.050 0.050 0.050 423,900 21,195.00 17
17/03/2020 0.045 0.060 0.045 0.055 902,500 46,110.50 34
16/03/2020 0.055 0.055 0.045 0.045 697,400 34,728.00

Bintai the con n goreng stock
52 week High n Low

From low of 0.04 to high of 1.47 n close 1.12 already 3000%

More than any gloves stock high

So guys dont kena cheated by these 2 con artist Victorino n joyvest

Ahh i forget to include another 1
That is the most famous fortune teller or maybe Nostradamus @paulthesotong

Bintai the con n goreng stock
52 week High n Low

From low of 0.04 to high of 1.47 n close 1.12 already 3000%

More than any gloves stock high

So guys dont kena cheated by these 2 con artist Victorino n joyvest

Next week Bintai the con stock will be like VIVOCOM limit down 2 x recently

Why not get my address too i m eager waiting 4 u n see what u can do to me
Really Betahan tututu

Victorino Safety 1st,you think everybody can joke with you? You like to play, I can play with you, I can get your address within a day...

Price History of con n goreng stock Bintai aka Bantai

Promote by 2 best snake oil salesman ie Victorino n joyvest



Date Open High Low Close Volume Value Transactions
Week : 33
13/08/2020 0.110 0.130 0.110 0.120 5.145m 605,445.50 160
12/08/2020 0.105 0.105 0.100 0.105 826,700 85,021.00 24
11/08/2020 0.110 0.115 0.110 0.110 692,400 76,449.00 35
10/08/2020 0.105 0.110 0.105 0.110 984,700 104,736.00 28
Week : 32
07/08/2020 0.115 0.120 0.110 0.110 1.529m 173,792.50 63
06/08/2020 0.110 0.115 0.105 0.110 2.537m 275,173.50 47
05/08/2020 0.100 0.110 0.100 0.110 1.112m 117,022.50 41
04/08/2020 0.100 0.100 0.095 0.100 280,200 27,320.00 14
03/08/2020 0.095 0.100 0.095 0.100 47,100 4,475.00 5
Week : 31
30/07/2020 0.100 0.105 0.100 0.100 130,300 13,031.00 5
29/07/2020 0.100 0.100 0.100 0.100 232,200 23,220.00 5
28/07/2020 0.100 0.105 0.100 0.105 378,400 37,846.50 20
27/07/2020 0.095 0.095 0.095 0.095 183,600 17,442.00 10
Week : 30
24/07/2020 0.090 0.100 0.090 0.100 25,200 2,445.00 5
23/07/2020 - 0.000 0.000 0.000 0 0.00 0
22/07/2020 0.090 0.100 0.090 0.100 226,400 21,389.50 12
21/07/2020 0.085 0.095 0.085 0.090 189,600 16,964.00 13
20/07/2020 0.090 0.100 0.090 0.095 540,100 49,886.00 30
Week : 29
17/07/2020 - 0.000 0.000 0.000 0 0.00 0
16/07/2020 0.095 0.100 0.095 0.095 573,300 54,963.50 19
15/07/2020 0.095 0.100 0.095 0.100 35,000 3,480.00 3
14/07/2020 0.100 0.100 0.100 0.100 36,700 3,670.00 4
13/07/2020 0.100 0.105 0.100 0.105 208,800 20,880.50


Date Open High Low Close Volume Value Transactions
Week : 16
13/04/2020 0.075 0.080 0.070 0.070 516,100 37,365.50 36
Week : 15
10/04/2020 0.085 0.085 0.080 0.085 234,100 18,831.50 16
09/04/2020 0.075 0.095 0.075 0.085 2.166m 182,322.00 121
08/04/2020 0.070 0.080 0.070 0.075 217,000 16,475.00 16
07/04/2020 0.070 0.080 0.065 0.070 112,800 7,930.00 11
06/04/2020 0.055 0.070 0.055 0.065 503,800 31,416.00 32
Week : 14
03/04/2020 0.055 0.055 0.055 0.055 37,600 2,068.00 4
02/04/2020 0.055 0.055 0.055 0.055 25,000 1,375.00 2
01/04/2020 0.050 0.055 0.050 0.055 97,600 5,330.00 7
31/03/2020 0.055 0.055 0.055 0.055 152,500 8,387.50 9
30/03/2020 0.055 0.055 0.050 0.050 202,500 10,375.00 12
Week : 13
27/03/2020 0.055 0.060 0.055 0.060 130,500 7,655.00 13
26/03/2020 0.050 0.060 0.050 0.055 80,500 4,177.00 7
25/03/2020 0.060 0.060 0.050 0.055 268,400 15,554.00 12
24/03/2020 0.050 0.055 0.050 0.055 147,000 7,645.00 8
23/03/2020 0.045 0.050 0.045 0.045 202,000 9,490.00 13
Week : 12
20/03/2020 0.055 0.060 0.050 0.060 17,000 910.00 4
19/03/2020 0.060 0.060 0.040 0.060 514,100 24,226.50 25
18/03/2020 0.070 0.070 0.065 0.065 433,600 29,337.00 19
17/03/2020 0.070 0.075 0.070 0.075 208,900 14,744.00 22
16/03/2020 0.080 0.090 0.080 0.090 110,500 8,845.00

Those who got some status in society only have the opportunity to know TSLYW or family members
Not the Ah Chee Ah Kow who come here to talk kokok boast lies n mislead investor to buy con n goreng stock for their own benefits

Sooner or later sure kena sambar kilat

Victorino Sorry to tell you Mobbs68, one of the Lim family also I can call at anytime to order glove stocks. What lies..

Oh u know what is middle means ahh Victorino

This year BursaSino Best actor n actress goes tooooooooooooooooooooooooo

Victorino n joyvest

Yehhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

Victorino do u know what is middle finger to u

TP 3.50 ? Everybody rushing to take private TG

Telling lies n boasting sure kena sambar kilat

Victorino Trevor, I surrounding with people who is doing trade on the glove, how many containers and gred A or B just tell me. I can quote you the price and time of DELIVERY.WITH CE or FDA Not necessary to get from TG.

Bintai or kena Bantai afterall is a con/goreng stock

Victorino qualified to be best snake oil salesman in this i3 Forum n 2nd Best r joyvest

joyvest U r more like a snake oil salesman than a promoter of vaccine

KUALA LUMPUR, Dec 12 — Malaysia will not rush the approval of Covid-19 vaccines for “emergency use” as some other nations have done, said Khairy Jamaluddin.

The Science, Technology and Innovation minister said the country would ensure that any vaccines procured would go through thorough evaluation by the authorities to ensure their safety.

“In Malaysia, there will be no political pressure and we will not use the emergency-use pathway.

“The clinical data of the vaccines we procure will be independently evaluated by the [Health Ministry’s National Pharmaceutical Regulatory Agency] NPRA before it can be registered and used,” he said.

The minister was commenting on a report of the US Food and Drug Administration expediting approval for the Pfizer-Biontech vaccine due to pressure from the outgoing Trump administration.

Donald Trump is pushing for the vaccine to be rolled out before the formal transition to President-Elect Joe Biden next year in order to claim credit for his administration.

Malaysia has ordered the Pfizer-Biontech vaccine and an alternative from COVAX that would roughly cover 30 per cent of the population, which will be delivered in batches next year.

However, no country has yet given full regulatory approval to any Covid-19 vaccine candidate so far.

This has led to some sections here in Malaysia and elsewhere to express concern over the potential dangers and side effects that may have been overlooked in the rush to produce a reliable vaccine against the world-stopping Covid-19 pandemic.

The Health Ministry has repeatedly assured Malaysians that any and all vaccines to be used here will be fully studied and evaluated to ensure they are safe to use.

Malaysia is grappling with a third wave of Covid-19 infections that has pushed the country’s total cases to over 80,000.

What talking U joyvest , Bintai Generex vaccine is USA product and nothing to do with China
Are nuts already joyvest KKK KKS

KaKiKong KaKiSong

tut tut


joyvest Yeap...according to the news,china vaccine is more superior to pfizer and moderna because

no1.china one is easier in terms of logistics as It need to be stored in temperature of 7- 8 c as compared to pfizer and moderna which require extreme high cold temperature

No2.china one is made of the substance which causes lesser side effect

No.3.there are more signs that many countries are more likely to opt for the more acceptable china vaccine...

6998 BINTAI BINTAI KINDEN CORPORATION BHD
MEMORANDUM OF UNDERSTANDING

MEMORANDUM OF UNDERSTANDING
Bintai Kinden Corporation Berhad- Memorandum of Understanding between Bintai
Healthcare Sdn Bhd and Generex Biotechnology Corporation (Generex) and
NuGenerex Immuno-Oncology (NuGenerex)
You are advised to read the entire contents of the announcement or attachment.
To read the entire contents of the announcement or attachment, please access
the Bursa website at http://www.bursamalaysia.com


25/11/2020 07:00 AM

What talking U joyvest , Bintai Generex vaccine is USA product and nothing to do with China
Are nuts already joyvest KKK KKS

KaKiKong KaKiSong

tut tut

Keyman188 TG share issue 8.2 B x RM 3.5 = RM 24.43 B
FY 2021 forecast PAT at 12 B x 2 years = RM 24 B PAT


Keyman188 must be stupidity to the max or retarded , 2+2 = 2 laugh die me xiao xi ren

Keyman188 should go back to Kindergarten to learn math again

..........................................................

Keyman188 Really laugh die Keyman188...

Are you sure TSLWC will privatise his company if drop to 5.00 !!!...

Keyman188 also wants bet with you...

Even though drop to below 50 cents, TSLWC also no intention or no interested to privatise...

You know why ???.......



Posted by mobbs68 > Dec 12, 2020 10:11 PM | Report Abuse

IF below 5.00 TSLWC will take private TG
No need share their guarantee profit of at least 12 B FY 2021 15 B 2022

Post removed.Why?

TG share issue 8.2 B x RM 3.5 = RM 24.43 B
FY 2021 forecast PAT at 12 B x 2 years = RM 24 B PAT

Keyman188 must be stupidity to the max or retarded , 2+2 = 2 laugh die me xiao xi ren

Keyman188 should go back to Kindergarten to learn math again

Keyman188 Really laugh die Keyman188...

Are you sure TSLWC will privatise his company if drop to 5.00 !!!...

Keyman188 also wants bet with you...

Even though drop to below 50 cents, TSLWC also no intention or no interested to privatise...

You know why ???.......



Posted by mobbs68 > Dec 12, 2020 10:11 PM | Report Abuse

IF below 5.00 TSLWC will take private TG
No need share their guarantee profit of at least 12 B FY 2021 15 B 2022

TG share issue 8.2 B x RM 3.5 = RM 24.43 B
FY 2021 forecast PAT at 12 B x 2 years = RM 24 B PAT

Keyman188 must be stupidity to the max or retarded , 2+2 = 2 laugh die me xiao xi ren

Keyman188 should go back to Kindergarten to learn math again

Even retarded also will buy TG at 3.50 lah
JP Morgan not only stupid but dow syndrome

IF below 5.00 TSLWC will take private TG
No need share their guarantee profit of at least 12 B FY 2021 15 B 2022
12/12/2020 10:10 PM

JPM forecast TP 3.50 2022 for TG after Bonus issue 2 for 1 in end 2021 lah

That will 3 x 3.5 = 10.5

bikay101 If we fast forward to 2022, then it is easier to understand JP Morgan's $3.50
In 2022, TP will be $3.50
In 2022, covid 19 testing will drop a lot
In 2022, gloves supply will be higher than demand
In 2022, ASPs will drop
12/12/2020 7:31 PM